Results 71 to 80 of about 218,733 (151)

Clinical and Hormonal Criteria of the Effectiveness of Suppressive Cabergoline Therapy in Patients with Organic Hyperprolactinemia

Mìžnarodnij Endokrinologìčnij Žurnal, 2015
Background. In modern international guidelines, there are not distinguished criteria for the evaluation of clinical symptoms, including somatic, neurological status, although almost all neuroendocrinologists acknowledge the presence exactly of ...
O.O. Khyzhniak, T.H. Hohitidze, M.R. Mykytiuk   +2 more
doaj   +1 more source

The Heterogeneity of Serum hPRL in a Patient with a Giant Prolactinoma

Folia Endocrinologica Japonica, 1984
The heterogeneity of hPRL in the serum of a patient with a giant prolactinoma (hPRL 27 micrograms/ml) was studied employing gel chromatography, RIA and lymphoma cell bioassay. After gel filtration of serum sample on Sephadex G-100 (superfine) column, a few hPRL peaks were detected by RIA.
TANAKA, Toshiaki, AIBA, Tadashi, SHISHIBA, Yoshimasa   +2 more
openaire   +3 more sources

Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey

, 2015
Giant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma.
Turgut, Seda, Ilhan, Mahmut Muzaffer, Evran, Sevket, Hanimoglu, Hakan, Kaynar, Mehmet Yaşar, TAŞAN, ERTUĞRUL   +5 more
core  

Giant prolactinoma: case report

Objective: To report the clinical case of an adolescent with a giant prolactinoma, diagnosed at the pediatric endocrinology service of a public university hospital in Salvador, Bahia.
Ferreira, Juliane Moreira
core   +1 more source

Rapid Visual Improvement After Cabergoline Therapy in a Macroprolactinoma Case

Endocrinology Research and Practice, 2018
Introduction: Medical therapy with dopamin agonists (DAs) is the first treatment of choice for prolactinomas. no matter how large or how severe the neurologic sequelae and cabergoline (CAB) is the best initial choice (1).
Elif Güneş, Şirin Zelal Şahin Tırnova, Erdinç Ertürk   +2 more
doaj   +1 more source

OBSTACLES IN MANAGING GIANT PROLACTINOMA

Journal of the ASEAN Federation of Endocrine Societies
INTRODUCTION/BACKGROUNDSarcoidosis is a multisystem granulomatous inflammatory disorder with common involvement of the lungs, lymph nodes and heart. Neurosarcoidosis, especially hypothalamicpituitary involvement, is a rare phenomenon (<10% of sarcoidosis patients).
Siti Zakiah Ahmad Daud, Syarifah Syahirah Syed Abas, Nor Afidah Karim, Yong Lit Sin, Noor Lita Adam   +4 more
openaire   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas

Endocrine Oncology
Functional pituitary tumours, also called pituitary neuroendocrine tumours (PitNETs), typically produce a single hormone, based on the cell lineage from which they arise in the anterior pituitary.
James M McNeil, Nicholas C Candy, Alistair K Jukes, Sunita M C De Sousa   +3 more
doaj   +1 more source

A "giant" prolactinoma [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1997
Reuter, Uwe, Mehraein, Susan, Arnold, Gerhard, Lehmann, Rüdiger   +3 more
openaire   +3 more sources

Case report and literature review of pituitary apoplexy in a 14-year-old girl with prolactinoma

Discover Medicine
Background Pituitary adenomas are rare in pediatric populations, with prolactinomas representing 20–39% of childhood cases. Pituitary apoplexy-hemorrhage or infarction of a pituitary adenoma-occurs in only 2–12% of tumors and is exceedingly uncommon in ...
Xuewen Yuan, Jiexin Yu, Xinfa Wang, Wei Gu   +3 more
doaj   +1 more source